ResMed’s latest quarterly earnings have painted a complex picture for investors. The medical technology specialist delivered fundamentally strong results, yet conflicting indicators from corporate insiders and market analysts are creating an atmosphere of uncertainty. The central question remains: is the company poised for a significant breakout, or is a period of consolidation on the horizon?
Analyst Consensus Shows Divergent Paths
The analyst community is deeply divided on ResMed’s outlook. While a “Moderate Buy” rating currently prevails, the disparity in price targets is significant. The Royal Bank of Canada reinforced its “Outperform” stance by raising its target to $303. Citigroup initiated coverage with an even more bullish outlook, issuing a “Buy” rating and a $330 price objective.
However, this optimism is tempered by more cautious voices. Stifel Nicolaus maintained its “Hold” position despite increasing its target to $270. Mizuho also displayed slight reservation, trimming its target from $310 to $300. This wide range of expectations, with a consensus target of $297.45, highlights the market’s indecision regarding the stock’s future potential.
Strong Fundamentals Underpin the Business
The company’s financial health appears robust. For the first quarter of 2026, ResMed reported a 9% revenue increase to $1.3 billion, surpassing market forecasts. Profitability metrics were even more compelling, with the operating margin expanding by a substantial 290 basis points to reach 61.5%. Adjusted earnings per share came in at $2.55, clearly beating the analyst estimate of $2.49.
Should investors sell immediately? Or is it worth buying Resmed?
Further reinforcing this solid foundation was an operating cash flow of $457 million, underscoring the company’s financial stability and operational efficiency.
Conflicting Moves from Major Players
A clear divergence in behavior is evident between institutional investors and company insiders. On one hand, major funds are building their stakes. The Ontario Teachers Pension Plan Board established a new position, while Intech Investment Management significantly boosted its existing holding by 45%.
In stark contrast, internal decision-makers have been net sellers over the past 90 days. Most notably, CEO Michael Farrell sold shares worth $2 million in early November at a weighted average price of $249.75. This trend of insider selling often serves as a cautionary signal for the market.
- Q1 Revenue: $1.3 billion (+9%)
- Adjusted EPS: $2.55 (Estimate: $2.49)
- Institutional Ownership: 54.98%
- Dividend: $0.60 per share
- Consensus Price Target: $297.45
Trading at a current price of $246.22, ResMed’s shares remain notably below their 52-week high of $293.81. The upcoming annual general meeting could provide fresh momentum, but the mixed signals from both within the company and the analyst sphere are giving investors pause. The battle for a definitive trend reversal continues.
Ad
Resmed Stock: Buy or Sell?! New Resmed Analysis from November 19 delivers the answer:
The latest Resmed figures speak for themselves: Urgent action needed for Resmed investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 19.
Resmed: Buy or sell? Read more here...
